BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Enters Strategic Agreement to Offer World-Class RPM Solution to HCPs Across the UK and Ireland

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, today announced its entry into a new strategic partnership with Williams Medical to make the DarioHealth Remote Patient Monitoring (“RPM”) digital therapeutics platform available to Healthcare Professionals (“HCPs”) across the United Kingdom and Ireland. According to the update, Dario’s turn-key RPM solution integrates the company’s existing open platform, application technology, and the DarioEngage coaching platform, to allow Healthcare Professionals to monitor their patients remotely. “We are very excited about this partnership between DarioHealth and Williams Medical, as this aligns with our international growth initiative by offering our world-class RPM platform to physicians outside of the United States,” Dror Bacher, COO of DarioHealth, stated in the news release. “Williams’ in-depth understanding of the UK and Irish healthcare markets and strong presence in the primary care arena creates an ideal opportunity for us to deliver a best-in-class RPM solution to general practices and patients, which we believe leads to reduced HCP workload while enhancing patient care and clinical outcomes.”

To view the full press release, visit http://ibn.fm/EnSTL

About DarioHealth Corp.

DarioHealth Corp. (NASDAQ: DRIO) is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, DarioHealth empowers individuals to make adjustments to their daily lifestyle choices to improve their overall health. Its cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions, visit www.DarioHealth.com

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Earth Science Tech, Inc. (OTC: ETST) Shareholders Approve Uplisting Strategy, Series B Preferred Stock Retirement

Earth Science Tech (OTC: ETST) announced voting results from its first Annual Meeting of Stockholders, held virtually…

3 hours ago

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential

Disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE:…

2 days ago

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Moves Myelin-Protecting MS Therapy to Phase 2 Development

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ:…

6 days ago

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Expands GelrinC Clinical and Commercial Pathways

Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC cell-free cartilage repair implant along parallel U.S. clinical…

6 days ago

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Marks Growth as Avenvi Expands Asset Base

Earth Science Tech (OTC: ETST) was featured in a recent article that discussed its strengthened position…

6 days ago

BioMedNewsBreaks – NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) Completes Three Large-Animal Procedures Using StereoCED(TM) Platform

NeuroOne (NASDAQ: NMTC) reported the successful completion of three large-animal procedures using its next-generation StereoCED(TM) platform as part of…

6 days ago